News from regeneron pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 21, 2022, 07:00 ET Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol

Children already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their LDL-C...

May 20, 2022, 15:15 ET FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead ...

May 04, 2022, 06:30 ET Regeneron Reports First Quarter 2022 Financial and Operating Results

First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 25% First...

May 02, 2022, 16:15 ET Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities Healthcare Conference at 1:20 p.m....

Apr 19, 2022, 07:00 ET Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biopharmaceutical company focused ...

Apr 14, 2022, 07:00 ET U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months its...

Apr 07, 2022, 00:59 ET Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization...

Apr 05, 2022, 16:05 ET Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2022 financial and operating results on...

Apr 04, 2022, 00:59 ET FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority...

Mar 26, 2022, 09:59 ET Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis

Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful...

Feb 28, 2022, 16:02 ET Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed...

Feb 26, 2022, 12:04 ET Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis

Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with...

Feb 26, 2022, 11:59 ET Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria

In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to...

Feb 18, 2022, 00:59 ET Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program

In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in interim analysis despite numeric...

Feb 17, 2022, 16:05 ET Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Cowen 42nd Annual Health Care Conference at 1:30 p.m....

Feb 11, 2022, 07:50 ET Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting

Trial met primary safety endpoint and no new safety signals seen through week 44 Results favored aflibercept 8 mg in visual acuity, drying and other...

Feb 10, 2022, 00:59 ET FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled moderate-to-severe atopic dermatitis for these...

Feb 04, 2022, 06:30 ET Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

Fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributable to REGEN-COV®(2);...

Feb 01, 2022, 16:29 ET Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting

Late-breaking pivotal data show significant disease improvements in eosinophilic esophagitis and also in chronic spontaneous urticaria 18 abstracts...

Jan 31, 2022, 00:59 ET CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Recommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function in children aged 6...

Jan 28, 2022, 07:00 ET Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the voluntary withdrawal of the supplemental Biologics License Application...

Jan 20, 2022, 12:00 ET Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search

Over $3 Million to be Awarded in Oldest and Most Prestigious U.S. STEM Competition for High School Seniors Regeneron Pharmaceuticals, Inc. (NASDAQ:...

Jan 19, 2022, 07:00 ET FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC

Regulatory filing recently submitted in the European Union Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

Jan 19, 2022, 00:59 ET Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis

Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting...

Jan 13, 2022, 16:05 ET Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2021 financial and operating...